COPD and asthma devices market seen topping $95B by 2030

The market for COPD and asthma devices is projected to exceed $95 billion by 2030, driven by rising respiratory disease rates, aging populations and demand for home-based care. North America is expected to lead the market, while metered dose inhalers remain the biggest product category.

Why it matters: - COPD and asthma devices are becoming a larger piece of the medical equipment market as respiratory disease rates rise worldwide. - The market is projected to top $95 billion by 2030, underscoring continued demand for inhalers, nebulizers and connected respiratory care tools. - Growth in this category could shape treatment access, patient adherence and long-term disease management across hospitals and home care settings.

What happened: - The Business Research Company said the global COPD and asthma devices market is on track to exceed $95 billion by 2030. - The market is forecast to grow at a 7% compound annual growth rate through 2030. - North America is expected to remain the largest regional market, reaching $31 billion by 2030. - The U.S. is projected to be the top country in the market, with a value of $27 billion by 2030.

The details: - The report estimates the COPD and asthma devices segment will account for nearly 8% of the wider medical equipment industry by 2030. - The broader medical equipment market is forecast to reach $1,176 billion by 2030. - North America is projected to grow from $23 billion in 2025 to $31 billion in 2030, a 6% CAGR. - The U.S. market is expected to rise from $21 billion in 2025 to $27 billion in 2030, also at a 6% CAGR. - Metered dose inhalers are projected to be the largest product segment, representing 34% of the market and $32 billion in 2030. - The market covers inhalers and nebulizers across asthma and COPD use cases, including hospitals, clinics, home care, research institutions and pediatric, adult and geriatric users. - The report identifies AstraZeneca Plc as the 2025 market leader with a 10% share. - The top 10 companies held 21% of total revenue in 2025, pointing to a moderately fragmented market. - Key competitors include GlaxoSmithKline, Boehringer Ingelheim, Royal Philips, Teva, Novartis, Omron, Cipla and Chiesi. - Major raw material suppliers include Berry Global, West Pharmaceutical Services, AptarGroup, Gerresheimer, SCHOTT Pharma and several chemical and materials companies. - Major distributors include McKesson, Cencora, Cardinal Health, Medline, Henry Schein and Owens & Minor. - Named end users include Mayo Clinic, Cleveland Clinic, Kaiser Permanente, NHS England, Apollo Hospitals and Johns Hopkins Hospital. - The full report is available online. - A sample request is also available.

Between the lines: - Demand is being pushed by rising asthma and COPD prevalence, pollution, smoking, occupational exposure and aging populations. - The report says those drivers add 2.9% annual growth from disease burden, 2.8% from aging and 2.5% from home-based respiratory care. - The biggest opportunity appears to be portable, easier-to-use devices that support treatment outside traditional care settings. - Triple-combination inhalers and digital inhaler features are becoming a key competitive battleground as manufacturers push for better adherence and monitoring. - In April 2026, AstraZeneca received U.S. FDA approval for Breztri Aerosphere as an asthma maintenance therapy for patients 12 and older, expanding the product beyond COPD.

What's next: - The market is expected to keep growing as companies invest in smart connected inhalers, low-carbon device designs and AI-powered respiratory monitoring. - Innovation, regulatory approvals and partnerships are likely to determine which companies gain share in a still-fragmented market. - The strongest growth appears likely in metered dose inhalers, dry powder inhalers and other portable device categories as home care expands.

The bottom line: - COPD and asthma devices are shifting from a steady-care category to a growth market shaped by aging populations, connected technology and broader use of home-based treatment.